PAMSys as Secondary Endpoint for MSA | Digital Biomarkers Summit

Data presented by Alterity Therapeutics shows PAMSys data strongly correlates with clinical scales of motor impairment in Multiple System Atrophy (MSA). PAMSys is  being used as a secondary endpoint in the ATH434 Phase 2 trial in MSA.

BioSensics is excited to sponsor and attend the Digital Biomarkers & Digital Measurements Summit this week. Please visit our booth to see our gold-standard wearable devices and solutions for measurement of digital biomarkers in clinical trials and research.

LEGSys and BalanSens: First FDA-listed wearable devices for clinical gait and balance assessments. The devices have been used in 200+ clinical studies and trials, including the measurements of primary endpoints in 15+ clinical trials.

PAMSys: The most advanced wearable sensor for monitoring walking parameters, posture and postural transition, sedentary behavior, sleep and sleep quality, and falls during activities of daily living. PAMSys measures 40+ independent parameters of physical activity and has been used in 10+ clinical trials for collecting secondary and  primary endpoints. 

BioDigit Home: The most comprehensive solution for measurement of digital biomarkers in neurological and neuromuscular disorders. BioDigit Home includes over 100 digital assessments of motor, cognition, and speech functions, as well as mental health and complete ePRO/eCOA capabilities.

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. Our experienced research team provides comprehensive technical and scientific consulting, including study design and protocol development support, as well as statistical analysis. In addition, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.